Novartis AG annual return on assets (roa)
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novartis AG Return on Assets (ROA) Growth & History (NVS)
Novartis AG's return on assets (roa) was 13.10% for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 13.10% | +1.29 pp |
| 2024 | 2024-12-31 | 11.81% | −1.86 pp |
| 2023 | 2023-12-31 | 13.67% | +8.08 pp |
| 2022 | 2022-12-31 | 5.58% | −12.92 pp |
| 2021 | 2021-12-31 | 18.51% | +11.95 pp |
| 2020 | 2020-12-31 | 6.56% | −2.34 pp |
| 2019 | 2019-12-31 | 8.89% | −0.16 pp |
| 2018 | 2018-12-31 | 9.05% | +3.20 pp |
| 2017 | 2017-12-31 | 5.85% | — |
Novartis AG quarterly return on assets (roa)
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 11.27% | — |
| Q1 2026 | 2026-03-31 | 12.24% | — |
Novartis AG return on assets (roa) trends
Over the last five fiscal years, Novartis AG's return on assets (roa) increased from 6.56% to 13.10%, a change of +6.54 percentage points. The latest reported quarter, Q2 2026, shows 11.27%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...